Press release
Bispecific Antibody Competitive Landscape, Analytical Perspective, Therapeutics Assessment, Preclinical and Discovery Stage Products Report 2025
Request a sample and discover the recent advances in Bispecific Antibody Drugs @ https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape [https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Bispecific Antibody Competitive Landscape Report
* On February 19, 2026- Merus B.V. initiated a phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naive or have progressed after receiving prior therapy for advanced/metastatic disease.
* On February 18, 2026- Regeneron Pharmaceuticals announced a phase 2 study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin [PLD]), referred to as "combination drugs'.
* On February 18, 2026- AstraZeneca initiated a Phase II study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) and/or in combination with anticancer agents (COMBO) in participants with advanced hepatobiliary cancer (e.g., HCC, BTC, etc.).
* On February 13, 2026- Janssen Pharmaceutical K.K. conducted a phase 1/2 study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy of teclistamab at RP2D for Japanese participants in Phase 2 part.
* On February 13, 2026- Genmab announced a phase 1b/2 trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD; if reached) as well as establish the safety profile of epcoritamab monotherapy and epcoritamab + venetoclax in participants with R/R CLL.
* DelveInsight's Bispecific Antibody report depicts a robust space with 180+ active players working to develop 250+ pipeline therapies for Bispecific Antibody treatment.
* The leading companies working in the Bispecific Antibody Competitive landscape include Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim, and others.
* Promising Bispecific Antibody Therapies in the various stages of development include SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin , and others.
The Bispecific Antibody competitive landscape report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing, and acquisition - deal values trends. The sub-segmentation is described in the Bispecific Antibody report which provides company-company collaboration (licensing/partnering), company academic collaboration, and acquisition analysis in tabulated form.
Bispecific Antibody Overview
Immunoglobulins (antibodies [Abs]) are major protein components of the adaptive immune system, directed against foreign compounds and infectious agents. The IgG molecule consists of two light and two heavy chains connected by disulfide bonds; IgG is a monomer with a molecular weight of 146-160 kDa. Antigen-binding centers of Abs are formed by hypervariable regions of heavy and light chains. In the classical point of view, the Ab molecule contains two identical antigen-binding sites (two HL fragments) and is monospecific and bivalent.
Find out more about Bispecific Antibody Analytical Perspective: In-depth Commercial Assessment @ Bispecific Antibody Collaboration Analysis by Companies [https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Bispecific Antibody Competitive Landscape
The Bispecific Antibody competitive landscape report comprises of comparative assessment of Companies (by therapy, development stage, and technology).
Bispecific Antibody Report Assessment
* Bispecific Antibody Company Analysis
* Bispecific Antibody Therapeutic Assessment
* Bispecific Antibody Pipeline Assessment
* Inactive drugs assessment
* Bispecific Antibody Unmet Needs
Learn more about the emerging Bispecific Antibody Competitive Landscape @ Bispecific Antibody Market Drivers and Barriers, Unmet Needs [https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Bispecific Antibody Report
* Coverage- Global
* Bispecific Antibody Therapeutics Assessment: Product Type, Stage and Product Type, Route of Administration, Molecule Type
* Bispecific Antibody Companies- Janssen, Amgen, Akeso, Zymeworks, Roche, IGM Biosciences, MacroGenics, Provention Bio, Jiangsu Alphamab Biopharmaceuticals, Sichuan Baili Pharmaceutical, Regeneron Pharmaceuticals, Boehringer Ingelheim , and others.
* Bispecific Antibody Therapies- SI-B003, AK104, Bevacizumab, Paclitaxel, AK112, LY3434172, CDX-527, Etoposide, Carboplatin , and others.
Dive deep into rich insights for new drugs for Bispecific Antibody Product Developmental Activities, Visit @ Bispecific Antibody Research and Development Activities [https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Bispecific antibody: Overview
* Bispecific Antibody -Analytical Perspective: In-depth Commercial Assessment
* Competitive Landscape
* Therapeutic Assessment
* Bispecific antibody: Company and Product Profiles (Marketed Therapies)
* Janssen
* Amivantamab
* Bispecific antibody: Company and Product Profiles (Pipeline Therapies)
* Late Stage Products (Phase III)
* Akeso
* Ivonescimab
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IGM Biosciences
* Imvotamab
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* MacroGenics
* MGD024
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Company Name
* Product Name
* Drug profiles in the detailed report.....
* Inactive Products
* Bispecific antibody- Unmet needs
* Bispecific antibody - Market drivers and barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bispecific-antibody-competitive-landscape-analytical-perspective-therapeutics-assessment-preclinical-and-discovery-stage-products-report-2025]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bispecific Antibody Competitive Landscape, Analytical Perspective, Therapeutics Assessment, Preclinical and Discovery Stage Products Report 2025 here
News-ID: 4399767 • Views: …
More Releases from ABNewswire
Interior Painting Contractor in Philadelphia, PA, Observes Spring Surge as Homeo …
Philadelphia, PA - As temperatures warm and daylight extends, Beauty Walls and Floor is experiencing the annual spring surge that owner Sviat Oleksyuk has come to anticipate each year. The seasonal shift brings a wave of homeowners eager to refresh their living spaces, transforming interiors that may have been neglected during the darker winter months.
"Summer is the best, as well as spring time, when people get inspired with new ideas…
Modern Mountain Home Architects in Asheville, NC Complete Two-Volume Residence o …
Asheville, NC - Vellum Architecture & Design has completed the Windcliff Residence, a striking two-volume private residence positioned at 3,200 feet above sea level on a dramatic ridgeline site in Poplar Ridge. Designed for a professional couple from Florida seeking a modern mountain retreat, the project exemplifies thoughtful integration with the Blue Ridge landscape while navigating stringent height restrictions and complex topography.
The residence's distinctive composition features two volumes connected by…
Motorcycle Accident Lawyer in Vero Beach, FL, Notes Left-Turn Collisions Remain …
Vero Beach, FL - Left-turn collisions continue to represent the most dangerous and frequently occurring type of motorcycle crash in Indian River County, according to analysis from Graves Thomas Injury Law Group in Vero Beach. These intersection accidents typically occur when drivers turning left misjudge an approaching motorcycle's speed or fail to see the rider entirely, resulting in catastrophic impacts that often cause life-altering injuries or fatalities.
Joseph H. Graves, Founder…
Bipolar Depression Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Com …
DelveInsight's, "Bipolar Depression Pipeline Insight 2026" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Bipolar Depression pipeline landscape. It covers the Bipolar Depression Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bipolar Depression Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in…
More Releases for Bispecific
Global Bispecific Antibody Market Size Bispecific Antibodies Clinical Trials FDA …
Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
• Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
• Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2023)
• Global Bispecific Antibodies Market Size 2023: > USD 8 Billion
• Global Bispecific Antibodies Market Forecast Till 2029
• Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2023)
• Approved Bispecific Antibodies Regional Sales (2018 till 2023)
• Clinical and Commercial Insight On Approved…
Bispecific Drug Innovation - Creative Biolabs Concludes Its Journey at the 15th …
On September 5, Creative Biolabs successfully concluded its participation in the 15th Annual World Bispecific Summit.
New York, USA - September 10, 2024 - The summit brought together leading experts in the bispecific antibody [https://www.creative-biolabs.com/bsab/bispecific-antibody-bsab-development-service.htm] (BsAb) field from around the globe, offering attendees a rich platform to discuss cutting-edge developments and future directions.
Image: https://www.getnews.info/uploads/b7ea13d648fcb7917ba9b55571b2ba35.png
In recent years, this field has grown rapidly, becoming a focal point in biopharmaceutical research and development. A…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
Bispecific Antibodies: Revolutionizing Targeted Cancer Therapy
Bispecific antibodies (BsAbs) are revolutionizing targeted cancer therapy by offering a dual-targeting approach that enhances therapeutic efficacy and addresses tumor heterogeneity. These engineered antibodies are designed to recognize and bind two different antigens simultaneously, providing a more comprehensive attack on cancer cells and improving treatment outcomes.
One of the most successful examples of BsAbs is blinatumomab, which targets CD19 on B-cells and CD3 on T-cells. Blinatumomab has shown remarkable efficacy in…
Global Bispecific Antibody Market Research Report Forecast 2017 to 2021Global Bi …
Report Hive Market Research Released a New Research Report of 119 pages on Title " Global Bispecific Antibody Market Research Report Forecast 2017 to 2021 "with detailed Analysis, Forecast and Strategies.
The Global Bispecific Antibody Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Bispecific Antibody industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as…
Bispecific Antibodies Market - Global Industry Analysis 2024
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies…
